Zevra Therapeutics Q3 revenue rises 45% on MIPLYFFA sales
ZVRA•Zevra Therapeutics' third-quarter revenue rose 45% year over year to $37.76 million, beating the $37.08 million analyst consensus, driven by MIPLYFFA sales. The company reported net income of $19.21 million and ended the quarter with $270.9 million in cash.
1. Revenue and income
Zevra Therapeutics said third-quarter revenue rose 45% year over year to $37.76 million, above the $37.08 million consensus estimate from nine analysts. The company reported net income of $19.21 million, reversing a loss a year earlier, and income from operations of $11.58 million.
2. Pipeline and outlook
The company attributed revenue growth to sales of MIPLYFFA for Niemann-Pick disease type C. It ended the quarter with $270.9 million in cash, said its financial resources were sufficient to support strategic priorities, and expects to file a supplemental new drug application for MIPLYFFA in infants under 24 months in the first quarter of 2027. Zevra is awaiting the outcome of a European Union re-examination for arimoclomol marketing authorization.
